Patient survival and safety with biologic therapy. Results of the Mexican National Registry Biobadamex 1.0;Terapia biológica: Sobrevida y seguridad en padecimientos reumáticos. Resultados del Registro Nacional Biobadamex 1.0

Reumatologia Clinica

Volumn 8, Issue 4, 2012, Pages 189-194

  Ventura Ríos, Lucio ^a   Bañuelos Ramírez, David ^b   Hernández Quiroz, María del Carmen ^b   Robles San Román, Manuel ^c   Irazoque Palazuelos, Fedra ^d   Goycochea Robles, María Victoria ^b,e  

^a PEMEX   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c Centro Medico Toluca   (Mexico)

^d Hospital 20 de Noviembre   (Mexico)

^e Unidad de Investigación Colegio Mexicano de Reumatología   (Mexico)

Author keywords

Adverse effects; Anti TNF ; Arthritis; Biologic therapy

Indexed keywords

BIOLOGICAL PRODUCT;

ANKYLOSING SPONDYLITIS; ARTICLE; BIOLOGICAL THERAPY; DRUG SAFETY; HUMAN; INCIDENCE; INFECTION RATE; INFECTION RISK; JUVENILE RHEUMATOID ARTHRITIS; MEXICO; MORTALITY; MULTICENTER STUDY (TOPIC); POPULATION; POPULATION RISK; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SECONDARY ANALYSIS; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; INFECTION; KAPLAN-MEIER ESTIMATE; LUNG DISEASES; MALE; METABOLIC DISEASES; MEXICO; MIDDLE AGED; NEOPLASMS; PATIENT DROPOUTS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES;

EID: 84863322750     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2012.02.010     Document Type: Article

References (25)

1. Gabriel S., Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009, 19:229.
2. Peláez-Ballestas I., Sanin L.H., Moreno-Montoya J., Alvarez-Nemegyei J., Burgos-Vargas R., Garza-Elizondo M., et al. Epidemiology of the Rheumatic Diseases in Mexico. A Study of 5 Regions Based on the COPCORD Methodology. J Rheumatol Suppl 2011, 86:3-8. Grupo de Estudio Epidemiológico de Enfermedades Músculo Articulares (GEEMA).
3. Mould J., Peláez-Ballestas I., Vázquez-Mellado J., Terán-Estrada L., Esquivel-Valerio J., Ventura-Ríos L., Aceves-Avila F.J., et al. A multicenter study to assess the cost of rheumatoid Arthritis (RA), ankylosing spondylitis (AS), and gout. Gaceta Médica de México 2008, 144:225-231.
4. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis and Rheum 2008, 59:762-784. American College of Rheumatology.
5. Goycochea-Robles M.V., Arce-Salinas C.A., Guzmán S., Cardiel-Ríos M.H. Prescription rheumatology practices among Mexican specialists. Arch Med Res 2007, 38:354-359. on behalf of researchers of the First National survey of rheumatic diseases and quality of life in Mexico.
6. Smolen J.S., Landewé R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:946-975.
7. Chen Y.-F., Jobanputra P., Barton P., Jowet P., Bryan S., Claek W., et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults, and an economic evaluation of their cost-effectiveness. Health Technology Assessment 2006, 10. 1-229.
8. Curtis J.R., Singh J.A. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther 2011, 33:679-707.
9. Maradit-Kremers H. Methods to analyse real-world databases and registries Bull of the NYU. Hosp Joint Dis 2009, 67:193-197.
10. Curtis J., Jain A., Asklin S.L., Carmona L., Dixon W., Finchk A., et al. A comparison of patient characteristics and outcomes in selected European and US rheumatoid arthritis. Semin Arthritis Rheum 2010, 40:2-14.
11. Pérez-Zafrilla B., Descalzo M.A., Carmona L. Adverse reactions related to the administration of TNF inhibitors. Analysis of a registry of biologic therapy. Reumatol Clin 2008, 4:90-95. Biobadaser Study Group.
12. Carmona L. Actualizacion de Biobadaser. Reumatol Clin 2009, 5(S1):66-70. Grupo de estudio BIOBADASER.
13. Ventura L., Peña Ayala A. Registro de acontecimientos adversos con el uso de terapia biológica en enfermedades reumáticas en México: Biobadamex, informe preliminar (C099). Revista Reumatología Clínica 2009, 5(Suppl):66.
14. Lunt M., Watson K.D., Dixon W.G., Symmons D.P.M., Hyrich K.L. No evidence of association between Anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis & Rheum 2010, 62:3145-3153.
15. Carmona L., Gomez-Reino J. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006, 8R72. on behalf of the BIOBADASER GROUP. 10.1186/ar1941.
16. Marchesoni A., Zacarra E., Gorla R., Bazzani C.H., Puttini S., Atzeni F., et al. TNF-Alfa Antagonist survival rate in a cohort of rheumatoid arthritis patients, observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009, 1173:837-846.
17. Pérez-Sola M.J., Torre-Cisneros J., Pérez-Zafrilla B., Carmona L., Descalzo M.A., Gómez-Reino J.J. Infections in patients treated with tumor necrosis factor antagonists, incidence, etiology and mortality in the Biobadaser group. Med Clin (Barc) 2011, 137:533-540. Biobadaser study group.
18. Singh J.A., Wells G.A., Christensen R., Tanjong Ghogomu E., Maxwell L., McDonald J.K., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Chocrane Database Syst Rev 2011, 16:CD008794.
19. Titton D.C., Guimaraes Silveira I., Louzada-Junior P., Hayata A.L., Carvalho H.M.S., Ranza R., et al. Brazilian Biologic Registry: BiobadaBrasil implentation process and prleiminary results. Rev Bras Reumatol 2011, 51:145-160.
20. Lacaille D., Guh D.P., Abrahamowicz M., Anis A.H., Esdaile J.M. Nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008, 59:1074-1081.
21. Gomez-Reino J.J., Carmona L., Rodríguez-Valverde V., Martín-Mola E., Montero M.D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum 2003, 48:2122-21227. on behalf of the Biobadaser Group.
22. Gomez-Reino J.J., Carmona L., Descalzo M.A. Risk of tuberculosis in patients treated with tumor necrosis factor antagonist due to incomplete prevention of reactivation of latent infection. Arthritis and Rheum 2007, 57:756-761. for the Biobadaser group.
23. Carmona L., Descalzo M.A., Pérez-Pampin E., Ruiz-Montesino D., Erra A., Cobo T., et al. All cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor. Ann Rheum Dis 2007, 66:880-885.
24. Adebajo A., Furst D. Biologics agents and their use in resource poor countries. Editorial. J Rheumatol 2005, 32:7.
25. Katz P., Yelin E., Patel V., Huang X., Chiou ChF. Patient-reported outcomes following biologic therapy in a sample of adults with rheumatoid arthritis recruited from community-based rheumatologists. Arthritis Rheum 2009, 61:593-599.